Obesity Clinical Trial
Official title:
Postprandial Glycemia and Satiety of Meals With Potatoes, With and Without Protein
NCT number | NCT05610124 |
Other study ID # | 43406 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 1, 2023 |
Est. completion date | April 30, 2024 |
The proposed study aims to simulate a meal eaten at home, where meals will provide a fixed amount of protein from beef or vegetarian substitute "meat" balls with ad libitum access to one of mashed potatoes, full-fat fries, or pasta. Postprandial glycemia (PPG), insulin, active ghrelin, satiety, amino acid response and food intake (FI) at the meal and again 3h later (after an ad libitum pizza meal) will be measured. In addition, post-meal PPG and satiety will be measured for one hour after the second meal.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | April 30, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - > 18 and < 45 years of age - BMI > 18.5 and < 24.9 kg/m2 - Willing to maintain habitual diet, physical activity pattern, and body weight throughout the study. - Willing to maintain current dietary supplement use throughout the study. On test days, subject agrees not to take any dietary supplements until dismissal from the Nutrition Intervention Center. Failure to comply will result in a rescheduled test visit. - Willing to abstain from alcohol consumption for 24h prior to all test visits. - Willing to refrain from marijuana/ edibles use for the duration of the study (approximately 6 weeks). - Willing to avoid vigorous physical activity for 24h prior to all test visits. - Understanding the study procedure and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator. Exclusion Criteria: - Smoking - Thyroid problems - Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, a malabsorptive syndrome, pancreatitis, gallbladder or biliary disease. - Presence of a gastrointestinal disorder or surgeries within the past year. - Known to be pregnant or lactating. - Unwillingness or inability to comply with the experimental procedures and to follow our safety guidelines. - Known intolerances, sensitivity or allergy to any ingredients in the study products. - Extreme dietary habits (i.e Atkins diet, very high protein diets, etc.) or restrained eaters, identified by a score of = 11 on the Eating Habits Questionnaire - Uncontrolled hypertension (systolic blood pressure > 140 mm Hg or diastolic blood pressure > 90 mm Hg) as defined by the average blood pressure measured at screening. - Weight gain or loss of at least 10lbs in previous three months. - Excessive alcohol intake (more than 2 drinks per day or more than 9 drinks per week). - Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect blood glucose or that could affect the outcome of the study as per investigator's judgment. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Toronto - Department of Nutritional Sciences | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Toronto | Alliance for Potato Research and Education |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Blood Glucose Levels | Blood glucose level (mmol/L) is measured using finger prick capillary blood samples or intravenous blood samples. | Starting at the beginning of each session (0 minutes before consumption of treatment meal) and every 15-30 minutes up to 180 - 240 minutes (time of completion of each session). | |
Primary | Food Intake | Food intake at the treatment meal time will be measured by weighing the carbohydrates (CHO) sides plates after the assigned meal time. | After 30 minutes of the treatment meal start. | |
Secondary | Change in Insulin Levels | Level of blood insulin (µU/mL) is measured using finger prick capillary blood samples or intravenous blood samples. | Starting at the beginning of each session (0 minutes before consumption of treatment meal) and every 30 minutes up to 180 - 240 minutes (time of completion of each session). | |
Secondary | Change in Active Ghrelin Levels | Active ghrelin hormone concentrations (µmol/L) is analyzed in intravenous blood samples. | Starting at the beginning of each session (0 minutes before consumption of treatment meal) and every 30 minutes up to 180 - 240 minutes (time of completion of each session). | |
Secondary | Change in Amino Acid Response (Protein quality) | Amino acid concentrations (µmol/L) is analyzed in intravenous blood samples to determine amino acid release. | Starting at the beginning of each session (0 minutes before consumption of treatment meal) and every 30 minutes up to 180 - 240 minutes (time of completion of each session). | |
Secondary | Food Intake Compensation | The food intake compensation after the second meal (ad libitum pizza meal) will be measured (g). | at 180 minutes after the treatment meals. | |
Secondary | Change in Subjective Appetite | Motivation to Eat Adaptive Visual Analogue Scales measured based on a score between 0 to 100. A higher score indicates higher outcome. | up to 180 - 240 minutes (time of completion of each session) | |
Secondary | Change in Physical comfort | Physical Comfort Visual Analogue Scales measured based on a score between 0 to 100. A higher score indicates higher outcome. | up to 180 - 240 minutes (time of completion of each session) | |
Secondary | Change in Energy Level | Energy Level Visual Analogue Scales measured based on a score between 0 to 100. A higher score indicates higher outcome. | up to 180 - 240 minutes (time of completion of each session) | |
Secondary | Treatment palatability | Treatment Palatability Visual Analogue Scales measured based on a score between 0 to 100. A higher score indicates higher outcome. | Immediately after treatment meal consumption | |
Secondary | Change in Fatigue Level | Fatigue Level Visual Analogue Scales measured based on a score between 0 to 100. A higher score indicates higher outcome. | up to 180 - 240 minutes (time of completion of each session) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |